Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04787302 · ClinicalTrials.gov registry record · Phase 1
PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing
A Phase 1 study, sponsored by Cerevel Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04787302: Completed Phase 1 study, sponsored by Cerevel Therapeutics.
NCT04787302 is a Phase 1 study that has completed, run by Cerevel Therapeutics. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04787302, a Phase 1 study, has completed, sponsored by Cerevel Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
PET Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Oral Dosing
Primary Outcome
Fraction of M4 receptors occupied by CVL-231 doses
Interventions
- DRUG CVL-231
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2023-07-14 |
| Phase | Phase 1 |
What the finished NCT04787302 record still lists
NCT04787302 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 1 intervention - of which CVL-231 is the first listed.
NCT04787302 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04787302 about?
NCT04787302 is a clinical study titled "PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing". PET Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Oral Dosing
What is the current status of trial NCT04787302?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-06-01. Estimated completion is 2023-07-14.
What interventions are being tested in trial NCT04787302?
The interventions under investigation include: CVL-231 (DRUG).
Who is sponsoring clinical trial NCT04787302?
This trial is sponsored by Cerevel Therapeutics, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04787302's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI